Prothena Corporation plc: Form 10-Q Summary
Business Context and Reporting Period
Prothena is an Ireland-incorporated late-stage clinical biotechnology company developing antibody-based immunotherapies for amyloidosis, Parkinson’s disease and related synucleinopathies, psoriasis and other inflammatory diseases. The filing covers the quarter and six months ended June 30, 2015. Its principal programs were NEOD001, PRX002 and PRX003. The ordinary shares traded on Nasdaq under the symbol PRTA, with 31.4 million shares outstanding as of July 24, 2015.
Financial Results and Key Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Total revenue | $0.3 million, versus $15.1 million in 2014 | $0.9 million, versus $47.4 million in 2014 |
| Research and development expense | $12.8 million, up 48% | $23.4 million, up 30% |
| General and administrative expense | $5.5 million, up 12% | $10.6 million, up 8% |
| Operating loss | $18.0 million, versus operating income of $1.6 million | $33.1 million, versus operating income of $19.6 million |
| Net income (loss) | $(18.3) million, versus net income of $1.3 million | $(33.5) million, versus net income of $19.1 million |
| Basic and diluted loss per share | $(0.59), versus $0.06 earnings | $(1.15), versus $0.87 basic earnings |
| Net cash provided by (used in) operating activities | $(25.9) million for the six months, versus $24.1 million provided in 2014 |
Revenue and profitability margins deteriorated sharply because the 2014 comparable periods included Roche’s $30.0 million upfront payment, a $15.0 million clinical milestone and substantial reimbursed development costs. Based on reported figures, the operating margin was approximately negative 6,488% for the quarter and negative 3,794% for the six-month period; these percentages are not economically meaningful given the very small revenue base.
Cash and cash equivalents were $402.4 million at June 30, 2015, including $368.6 million in money market funds, compared with $293.6 million at December 31, 2014. Working capital was $392.7 million. Financing activities generated $134.7 million, primarily from the April 2015 equity offering, while investing activities used $0.1 million. The filing does not disclose outstanding conventional debt; total liabilities were $15.9 million, including $13.5 million of current liabilities.
Material Changes Versus the Prior Comparable Period
- Total revenue declined 98% for both the quarter and six months, primarily because no comparable Roche upfront or clinical milestone payment was recognized in 2015.
- R&D spending increased to support clinical development, especially NEOD001. Six-month NEOD001 R&D expense was $12.3 million, compared with $3.3 million in 2014.
- R&D expense included $1.3 million of payments to Roche during the six months and was reduced by $2.7 million of Roche development-cost reimbursements.
- The Roche arrangement reached the full $35.6 million allocated consideration recognized as license revenue. Future development reimbursements are expected to be recorded as offsets to R&D expense rather than as license revenue.
- Prothena completed an April 2015 underwritten offering of 3.795 million shares at $37.00 per share, generating approximately $131.4 million of net proceeds. Shares outstanding increased from 27.4 million at year-end 2014 to 31.4 million at June 30, 2015.
- Share-based compensation increased to $4.1 million for the six months from $2.8 million in 2014. Unrecognized compensation expense was estimated at $29.4 million at June 30, 2015.
Guidance, Outlook, Risks and Unusual Items
Management expects R&D expenses to increase in the second half of 2015, primarily because of the NEOD001 Phase 3 program and, to a lesser extent, the PRX003 Phase 1 program. G&A expenses were also expected to increase because of additional personnel, legal and administrative costs.
Management believed existing cash was sufficient to meet obligations for at least the next twelve months, but expected to require additional capital to continue development and eventual commercialization. Future financing could involve equity dilution, debt obligations or additional collaboration arrangements.
- NEOD001’s Phase 3 VITAL Amyloidosis Study was designed to enroll approximately 230 treatment-naive patients with cardiac dysfunction. An open-label Phase 1/2 expansion was also underway.
- PRX002 was being developed with Roche. Results from a Phase 1 single-dose study were described as well tolerated, with reductions in free serum alpha-synuclein of up to 96%; results from a multiple-ascending-dose Parkinson’s study were expected in the first half of 2016.
- PRX003 entered a Phase 1 study in June 2015, with enrollment planned for up to 40 subjects.
- The company depended on Roche for aspects of PRX002 development and on Boehringer Ingelheim for manufacturing clinical supplies. Supply, collaboration, clinical-trial, regulatory, intellectual-property and reimbursement failures could materially impair results.
- Contractual obligations totaled approximately $15.3 million, consisting primarily of operating leases of $11.3 million, purchase obligations of $2.6 million and license obligations of $1.4 million. Future Roche cost-sharing obligations were not determinable and were excluded.
- A $0.4 million loss was recognized on a facility sublease during the six months. No material legal proceedings or off-balance-sheet arrangements were reported.
Important Facts for Investors to Verify
- Whether NEOD001 Phase 3 enrollment, interim analysis and clinical outcomes remain on schedule and adequately funded.
- Whether PRX002 development milestones, Roche cost-sharing obligations and the 70% Roche/30% Prothena U.S. development and commercialization economics change.
- The pace of cash consumption as clinical programs expand and the timing and terms of any future financing.
- Whether Roche reimbursements continue to offset R&D expense and how this affects reported revenue comparability.
- Manufacturing capacity and supply continuity for clinical programs, particularly the company’s dependence on third-party manufacturers.
- Potential dilution from future equity offerings and the 3.29 million outstanding stock options at June 30, 2015.
- Regulatory, patent, clinical-trial and commercialization risks, noting that none of the company’s product candidates had received marketing approval.